Advertisement
Canada markets close in 2 hours 17 minutes
  • S&P/TSX

    22,769.39
    -44.36 (-0.19%)
     
  • S&P 500

    5,465.43
    -90.31 (-1.63%)
     
  • DOW

    40,054.44
    -303.65 (-0.75%)
     
  • CAD/USD

    0.7251
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    77.92
    +0.96 (+1.25%)
     
  • Bitcoin CAD

    91,957.54
    +1,058.13 (+1.16%)
     
  • CMC Crypto 200

    1,367.93
    +2.04 (+0.15%)
     
  • GOLD FUTURES

    2,416.60
    +9.30 (+0.39%)
     
  • RUSSELL 2000

    2,230.61
    -12.66 (-0.56%)
     
  • 10-Yr Bond

    4.2530
    +0.0140 (+0.33%)
     
  • NASDAQ

    17,513.30
    -484.05 (-2.69%)
     
  • VOLATILITY

    17.20
    +2.48 (+16.85%)
     
  • FTSE

    8,153.69
    -13.68 (-0.17%)
     
  • NIKKEI 225

    39,154.85
    -439.54 (-1.11%)
     
  • CAD/EUR

    0.6681
    -0.0001 (-0.01%)
     

Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised

Centene Corporation CNC reported first-quarter 2023 adjusted earnings per share (EPS) of $2.11, which lagged the Zacks Consensus Estimate by 5.4%. Nevertheless, the bottom line advanced 15.3% year over year.

Revenues of CNC amounted to $38,889 million, which improved 4.6% year over year. The top line outpaced the consensus mark by 7.1%.

The quarterly results took a hit from escalating medical costs. Nevertheless, the downside was partly offset by a growing premium base stemming from solid membership growth within most of its business lines and numerous contract wins.

Centene Corporation Price, Consensus and EPS Surprise

 

Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation Price, Consensus and EPS Surprise

Centene Corporation price-consensus-eps-surprise-chart | Centene Corporation Quote

 

Quarterly Operational Update

Revenues from Medicaid rose 5% year over year in the first quarter, while Medicare revenues grew 2% year over year. Meanwhile, commercial revenues climbed 27% year over year.

ADVERTISEMENT

Premiums of Centene improved 6.1% year over year to $33,825 million, higher than the Zacks Consensus Estimate of $33,104 million and our estimate of $32,936.5 million. This was due to solid membership growth of 52% in the Marketplace business as well as organic Medicaid growth.

Service revenues of $1,127 million dropped 51.9% year over year in the quarter under review. Yet, the metric beat the consensus mark of $816 million.

The total membership of CNC came in at 28.5 million as of Mar 31, 2023, which increased 8.5% year over year and surpassed our estimate of 27.4 million.

Health Benefits Ratio (HBR) of 87% improved 30 basis points (bps) year over year in the first quarter, thanks to disciplined Marketplace pricing and reduced Medicare utilization.

Centene reported net earnings of $1,130 million in the quarter under review, which surged 32.6% year over year.

Total operating expenses of $37,671 million increased 4.8% year over year. Medical costs rose 5.7% year over year to $29,434 million while selling, general and administrative expenses (“SG&A”) of $3,011 million escalated 9.7% year over year.

Adjusted SG&A expense ratio deteriorated 80 bps year over year to 8.5% in the first quarter. The metric suffered a blow from an expanding Marketplace business that operates at an increased SG&A ratio.

Financial Update (as of Mar 31, 2023)

Centene exited the first quarter with cash and cash equivalents of $15,853 million, which climbed 31.3% from the 2022-end figure. Total assets of $83 billion increased 8% from the figure at 2022 end.

Long-term debt amounted to $18,223 million, up 1.6% from the level as of Dec 31, 2022. The current portion of long-term debt amounted to $97 million.

Total stockholders’ equity of $25,166 million grew 4.1% from the 2022-end figure.

In the reported quarter, net operating cash flow of $4,269 million increased almost four-fold year over year.

Share Repurchase Update

Centene bought back 4.9 million shares worth $377 million in the first quarter. As of Apr 25, 2023, CNC had a leftover share buyback capacity of $2.2 billion.

2023 Guidance Revised

Premium and service revenues are currently forecasted between $135.2 billion and $137.2 billion, higher than the prior outlook of $131.5-$133.5 billion. The mid-point of the revised outlook indicates a rise of 0.5% from the 2022 reported figure.

Revenues are estimated to lie between $144.5 billion and $146.5 billion, up from the previous guidance of $137.4-$139.4 billion. The midpoint of the revised outlook implies a 0.7% improvement from the 2022 figure.

Management anticipates adjusted EPS to register a minimum of $6.40 this year, while the earlier view called for the metric to stay between $6.25 and $6.40. The mid-point of the updated outlook suggests a minimum growth of 10.7%  from the 2022 figure.

HBR is estimated in the 87.1-87.7% band, compared to the prior outlook of 87.2-87.8%. Adjusted SG&A expense ratio is expected within 8.7-9.1%, higher than the previous guidance of 8.2-8.7%. It also expects an adjusted effective tax rate of 24.1-25.1%.

Diluted shares outstanding are anticipated within 546.6-549.6 million.

2024 Outlook Trimmed

On the basis of an updated view of Medicaid redeterminations, Medicare bid strategy, and business investments, management estimates adjusted EPS to stay higher than $6.60 in 2024. The earlier view called for the metric to be a minimum of $7.15.

Long-Term Growth

Centene remains optimistic to achieve long-term adjusted earnings compound annual growth in the range of 12-15% in the second half of this decade.

Zacks Rank

Centene currently carries a Zacks Rank #3 (Hold).  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Other Medical Sector Releases

Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate.

Elevance Health’s first-quarter 2023 earnings of $9.46 per share beat the Zacks Consensus Estimate of $9.26 and our estimate of $9.22. Additionally, the bottom line advanced 15.5% year over year. ELV’s operating revenues improved 10.6% year over year to $41,898 million in the quarter under review. The top line beat the consensus mark by 2.5% and came higher than our estimate of $40,766.5 million. Medical membership of Elevance Health, as of Mar 31, 2023, totaled 48.1 million, which rose 2.9% year over year in the first quarter.

HCA Healthcare’s first-quarter 2023 adjusted earnings of $4.93 per share surpassed the Zacks Consensus Estimate by 23.6%. Also, the bottom line climbed 19.7% year over year. HCA’s revenues advanced 4.3% year over year to $15.6 billion. The top line beat the consensus mark by 2% and our estimate of $15.2 billion. While same-facility equivalent admissions rose 7.5% year over year in the first quarter, same-facility admissions improved 4.4% year over year.

Abbott Laboratories reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%. First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 1.1%. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Adjusted operating margin also contracted 827 bps to 20.5%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report

Centene Corporation (CNC) : Free Stock Analysis Report

Elevance Health, Inc. (ELV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research